NASDAQ: FRTX - Fresh Tracks Therapeutics, Inc.

Rentabilidad a seis meses: -15.91%
Sector: Healthcare

Calendario de promoción Fresh Tracks Therapeutics, Inc.

Horario avanzado gráfico sencillo
Financial Markets by TradingView

Acerca de la empresa

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States.

Más detalles
The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors. Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Añadir a la lista de comparación
Añadir a la lista de vigilancia
Añadir al portafolio
Añadir aviso de precio

Цена ао 0.88
Выручка 0.0079
EBITDA -0.0244
P/S 0.6067
P/BV 0.5855
EV/EBITDA 0.2897
ISIN US10802T2042
Сайт https://www.frtx.com
Число акций ао 0.00597 млрд
Валюта usd
IPO date 2022-09-08
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Cambio de precio por día: 0% (0.74)
Cambio de precio por semana.: +1.37% (0.73)
Cambio de precio por mes: -7.5% (0.8)
Cambio de precio en 3 meses.: -21.28% (0.94)
Cambio de precio en seis meses: -15.91% (0.88)
Cambio de precio por año: -26% (1)
Cambio de precio desde principios de año.: -20.43% (0.93)
Todos los parámetros

Subestimación

Nombre Significado Calificación
P/S 0.5982 10
P/BV 0.4823 10
P/E 0 0
EV/EBITDA 1.08 10
Total: 6.25

Eficiencia

Nombre Significado Calificación
ROA, % -49.15 0
ROE, % -57.34 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA 0 10
Total: 9.4

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 1.34 1
Rentabilidad Ebitda, % -76.95 0
Rentabilidad EPS, % -99.75 0
Total: 0.2
Más detalles

Instituciones Volumen Compartir, %
JBF Capital, Inc. 295000 4.94
Gts Securities LLC 50100 0.84
Virtu Financial LLC 43558 0.73
Geode Capital Management, LLC 41449 0.69
Vanguard Group Inc 23060 0.39
Tower Research Capital LLC (TRC) 10224 0.17
Blackrock Inc. 4790 0.08
Blue Trust, Inc. 916 0.02
Steward Partners Investment Advisory, LLC 709 0.01
Osaic Holdings Inc 43 0



Supervisor Título profesional Pago año de nacimiento
Mr. Albert Nicholas Marchio II CEO, CFO, Secretary & Chairman 251.83k 1952 (72 año)
Aron Aizenstat M.B.A., P.M.P. Vice President of Corporate Development & Operations N/A
Ms. Sue Fattor Head of Human Resource N/A
Dr. James S. McElvain Ph.D. Interim Head of CMC Development N/A
Mr. Aaron Fox-Collis CPA VP of Finance & Chief Accounting Officer N/A

DIRECCIÓN: United States, Boulder. CO, 5777 Central Avenue - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.frtx.com